Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Integrated analysis of proteome, phosphotyrosine-proteome, tyrosine-kinome, and tyrosine-phosphatome in acute myeloid leukemia.

Tong J, Helmy M, Cavalli FM, Jin L, St-Germain J, Karisch R, Taylor P, Minden MD, Taylor MD, Neel BG, Bader GD, Moran MF.

Proteomics. 2017 Mar;17(6). doi: 10.1002/pmic.201600361.

2.

Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1H)-pyrazole Derivatives as JAKs Inhibitors.

Liang X, Zang J, Zhu M, Gao Q, Wang B, Xu W, Zhang Y.

ACS Med Chem Lett. 2016 Aug 23;7(10):950-955. eCollection 2016 Oct 13.

3.

Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients.

Aasebø E, Forthun RB, Berven F, Selheim F, Hernandez-Valladares M.

Curr Pharm Biotechnol. 2016;17(1):52-70. Review.

4.

Phosphotyrosine profiling identifies ephrin receptor A2 as a potential therapeutic target in esophageal squamous-cell carcinoma.

Syed N, Barbhuiya MA, Pinto SM, Nirujogi RS, Renuse S, Datta KK, Khan AA, Srikumar K, Prasad TS, Kumar MV, Kumar RV, Chatterjee A, Pandey A, Gowda H.

Proteomics. 2015 Jan;15(2-3):374-82. doi: 10.1002/pmic.201400379.

5.

Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.

Cooper MJ, Cox NJ, Zimmerman EI, Dewar BJ, Duncan JS, Whittle MC, Nguyen TA, Jones LS, Ghose Roy S, Smalley DM, Kuan PF, Richards KL, Christopherson RI, Jin J, Frye SV, Johnson GL, Baldwin AS, Graves LM.

PLoS One. 2013 Jun 24;8(6):e66755. doi: 10.1371/journal.pone.0066755. Print 2013.

6.

Comparative proteomics in acute myeloid leukemia.

Luczak M, Kaźmierczak M, Hadschuh L, Lewandowski K, Komarnicki M, Figlerowicz M.

Contemp Oncol (Pozn). 2012;16(2):95-103. doi: 10.5114/wo.2012.28787. Epub 2012 May 29.

7.

Rapid Identification of Therapeutic Targets in Hematologic Malignancies via Functional Genomics.

Tyner JW.

Ther Adv Hematol. 2011 Apr;2(2):83-93. doi: 10.1177/2040620711403028.

8.

HIPK2 catalytic activity and subcellular localization are regulated by activation-loop Y354 autophosphorylation.

Siepi F, Gatti V, Camerini S, Crescenzi M, Soddu S.

Biochim Biophys Acta. 2013 Jun;1833(6):1443-53. doi: 10.1016/j.bbamcr.2013.02.018. Epub 2013 Feb 26.

9.

Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors.

Bai Y, Li J, Fang B, Edwards A, Zhang G, Bui M, Eschrich S, Altiok S, Koomen J, Haura EB.

Cancer Res. 2012 May 15;72(10):2501-11. doi: 10.1158/0008-5472.CAN-11-3015. Epub 2012 Mar 29.

10.

Multiple ETS family proteins regulate PF4 gene expression by binding to the same ETS binding site.

Okada Y, Nobori H, Shimizu M, Watanabe M, Yonekura M, Nakai T, Kamikawa Y, Wakimura A, Funahashi N, Naruse H, Watanabe A, Yamasaki D, Fukada S, Yasui K, Matsumoto K, Sato T, Kitajima K, Nakano T, Aird WC, Doi T.

PLoS One. 2011;6(9):e24837. doi: 10.1371/journal.pone.0024837. Epub 2011 Sep 12.

11.

Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling.

Pighi C, Gu TL, Dalai I, Barbi S, Parolini C, Bertolaso A, Pedron S, Parisi A, Ren J, Cecconi D, Chilosi M, Menestrina F, Zamò A.

Cell Oncol (Dordr). 2011 Apr;34(2):141-53. doi: 10.1007/s13402-011-0019-7. Epub 2011 Mar 11.

12.

Phosphoproteomics in cancer.

Harsha HC, Pandey A.

Mol Oncol. 2010 Dec;4(6):482-95. doi: 10.1016/j.molonc.2010.09.004. Epub 2010 Sep 26. Review.

13.

CCancer: a bird's eye view on gene lists reported in cancer-related studies.

Dietmann S, Lee W, Wong P, Rodchenkov I, Antonov AV.

Nucleic Acids Res. 2010 Jul;38(Web Server issue):W118-23. doi: 10.1093/nar/gkq515. Epub 2010 Jun 6.

14.

Tyrosine residues at the carboxyl terminus of Vav1 play an important role in regulation of its biological activity.

Lazer G, Pe'er L, Farago M, Machida K, Mayer BJ, Katzav S.

J Biol Chem. 2010 Jul 23;285(30):23075-85. doi: 10.1074/jbc.M109.094508. Epub 2010 May 10.

15.

RNAi screen for rapid therapeutic target identification in leukemia patients.

Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR, Willis SG, Erickson H, Kovacsovics T, O'Hare T, Heinrich MC, Druker BJ.

Proc Natl Acad Sci U S A. 2009 May 26;106(21):8695-700. doi: 10.1073/pnas.0903233106. Epub 2009 May 11.

16.

The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL.

Boccalatte FE, Voena C, Riganti C, Bosia A, D'Amico L, Riera L, Cheng M, Ruggeri B, Jensen ON, Goss VL, Lee K, Nardone J, Rush J, Polakiewicz RD, Comb MJ, Chiarle R, Inghirami G.

Blood. 2009 Mar 19;113(12):2776-90. doi: 10.1182/blood-2008-06-161018. Epub 2008 Oct 9.

17.

Proteomic contributions to personalized cancer care.

Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA, Jacobsen PB, Fenstermacher DA, Dalton WS.

Mol Cell Proteomics. 2008 Oct;7(10):1780-94. doi: 10.1074/mcp.R800002-MCP200. Epub 2008 Jul 29. Review.

18.

RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia.

Tyner JW, Walters DK, Willis SG, Luttropp M, Oost J, Loriaux M, Erickson H, Corbin AS, O'Hare T, Heinrich MC, Deininger MW, Druker BJ.

Blood. 2008 Feb 15;111(4):2238-45. Epub 2007 Nov 19.

19.

Quantitative time-resolved phosphoproteomic analysis of mast cell signaling.

Cao L, Yu K, Banh C, Nguyen V, Ritz A, Raphael BJ, Kawakami Y, Kawakami T, Salomon AR.

J Immunol. 2007 Nov 1;179(9):5864-76.

20.

A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia.

Gu TL, Mercher T, Tyner JW, Goss VL, Walters DK, Cornejo MG, Reeves C, Popova L, Lee K, Heinrich MC, Rush J, Daibata M, Miyoshi I, Gilliland DG, Druker BJ, Polakiewicz RD.

Blood. 2007 Jul 1;110(1):323-33. Epub 2007 Mar 14.

Supplemental Content

Support Center